Report Detail
European Markets for Chronic Obstructive Pulmonary Disease Products
Respiratory diseases affect all age groups, with more than 65 million people in Europe being affected and 1 in 7 deaths being caused by chronic lung disease. According to the European Lung Foundation (an arm of the European Respiratory Society), the annual economic burden of respiratory disease in Europe is estimated at €102.0 billion (or $128.6 billion), with lost work days accounting for 47.4% of costs, premature mortality and rehabilitation accounting for 19.6%, inpatient care accounting for 17.5%, outpatient care accounting for 8.9%, and prescription drugs accounting for the remaining 6.6%.
Pulmonary conditions that may require respiratory therapy include:
- acute respiratory distress syndrome
- asthma;
- chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema;
- cystic fibrosis;
- pneumonia;
- respiratory failure;
- restrictive lung disease; and,
- tuberculosis.
Nonpulmonary conditions that may require continuous respiratory therapy include neuromuscular disorders such as those associated with amyotrophic lateral sclerosis, poliomyelitis, scoliosis, and spinal cord injury.